Maintenance immunotherapy disappoints in SCLC
A trial found that overall survival was not significantly prolonged with combination immunotherapy, or with nivolumab alone.
Read More
Tag: primary endpoint
- Strong clinical data for Breye lead asset danegaptide
- EHP Awards triumph
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
